DBV Technologies to Engage in ACAAI 2024 Congress

DBV Technologies, a clinical-stage biopharmaceutical company, has announced its participation in the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. This event, set between October 24-28, 2024 in Boston, Massachusetts, will include a "Product Theater" session focused on optimal peanut allergy treatments, featuring key experts like Drs. Shahzad Mustafa and Edwin Kim, among others. Additionally, DBV will sponsor the 33rd Annual FIT Bowl, a competition on allergy knowledge.

Dr. Pharis Mohideen, Chief Medical Officer, highlighted the company's progress with the Viaskin® Peanut patch for children. Despite ongoing regulatory processes, DBV remains dedicated to addressing peanut allergy treatment needs. The Viaskin Peanut patch is a product candidate aiming to mitigate allergic reactions through epicutaneous immunotherapy.

While the Viaskin Peanut patch's safety and efficacy are yet to be confirmed by relevant authorities, DBV continues to engage the medical community to foster progress in allergy treatment.